MedTrace Logo

Genomic Signatures for Patients With Initially Unresectable Colorectal Liver Metastases

NCT06477718 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 286

Last updated 2024-06-27

No results posted yet for this study

Summary

A retrospective cohort of 286 patients with synchronous CRLM underwent conversion therapies based on next-generation sequencing (NGS) results. All cases were categorized into a successful conversion therapy group (SCTG) if they achieved no evidence of disease (NED) status through surgery after conversion therapy, and a failed conversion therapy group (FCTG) otherwise. Clinical risk factors and genomic mutations were analyzed for association with conversion therapy outcomes and survival.

Conditions

  • Genomic Instability
  • Prognostic Cancer Model

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Yueming Sun, Ph.D.;M.D. · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2018-12-01
Completion
2023-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06477718 on ClinicalTrials.gov